GeNeuro SA
GEM
Company Profile
Business description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact
3 chemin du Pre-Fleur
Plan-les-Ouates
Geneva1228
CHET: +41 225524800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
Shares screen as undervalued after prolonged decline.
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,139.90 | 34.50 | -0.38% |
| CAC 40 | 8,340.13 | 16.85 | 0.20% |
| DAX 40 | 24,983.42 | 31.45 | -0.13% |
| Dow JONES (US) | 50,334.00 | 198.13 | 0.40% |
| FTSE 100 | 10,361.22 | 25.01 | -0.24% |
| HKSE | 27,183.15 | 155.99 | 0.58% |
| NASDAQ | 23,246.43 | 7.76 | 0.03% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,513.68 | 67.31 | 0.50% |
| S&P 500 | 6,972.48 | 7.66 | 0.11% |
| S&P/ASX 200 | 8,867.40 | 44.20 | -0.50% |
| SSE Composite Index | 4,128.37 | 5.28 | 0.13% |